↑ 疾患リストへ ← 戻る

 90. 網膜色素変性症 [臨床試験数:78,薬物数:104(DrugBank:36),標的遺伝子数:36,標的パスウェイ数:23] 

Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod-Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04120883January 20204 November 2019Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)Oral Hydroxychloroquine for Retinitis Pigmentosa Caused by P23H-RHO (Substitution of Proline to Histidine at Codon 23 of the Rhodopsin Protein)Retinitis PigmentosaDrug: Hydroxychloroquine lower dose;Drug: Hydroxychloroquine higher doseUniversity of MichiganCures Within ReachNot recruiting18 YearsN/AAll12Phase 1/Phase 2United States
2NCT02018692December 1, 20194 March 2019The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis PigmentosaThe Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis PigmentosaRetinitis PigmentosaDietary Supplement: Alga Dunaliella Bardawil powder;Dietary Supplement: Placebo:StarchSheba Medical CenterNot recruiting12 Years18 YearsAll30Phase 1/Phase 2Israel
3NCT04123626October 7, 201922 October 2019A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO GeneA Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO GeneAutosomal Dominant Retinitis Pigmentosa;Eye Diseases;Eye Diseases, Hereditary;Retinal Dystrophies;Retinal Disease;Retinitis;Vision Tunnel;Vision DisordersDrug: QR-1123;Other: Sham procedureProQR TherapeuticsRecruiting18 YearsN/AAll35Phase 1/Phase 2United States
4NCT04068207September 23, 20197 October 2019Minocycline Treatment in Retinitis PigmentosaThe Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical TrialRetinitis Pigmentosa;Inherited Retinal Dystrophy;Retina DisorderDrug: MinocyclineSun Yat-sen UniversityRecruiting18 Years60 YearsAll35Phase 2China
5NCT03963154August 19, 201914 October 2019Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic MutationSTREAM: A Phase 1/2, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Implantation Into One Eye of hESC-derived RPE in Patients With Retinitis Pigmentosa Due to Monogenic MutationRetinitis PigmentosaBiological: Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)Centre d'Etude des Cellules SouchesRecruiting18 Years65 YearsAll12Phase 1/Phase 2France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03999021June 24, 201915 July 2019FIGHT-RP 1 Extension StudyA Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis PigmentosaRetinitis PigmentosaDrug: NAC effervescent tabletsJohns Hopkins UniversityRecruiting18 YearsN/AAll30Phase 1United States
7NCT03944239June 201920 May 2019Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis PigmentosaSafety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis PigmentosaRetinitis PigmentosaBiological: Retinal pigment epitheliums transplantationQi ZhouBeijing Tongren HospitalRecruiting18 Years80 YearsAll10Phase 1China
8NCT03780257March 6, 20194 November 2019Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A GeneA First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneRetinitis Pigmentosa;Usher Syndrome Type 2;Deaf Blind;Retinal Disease;Eye Diseases;Eye Diseases, Hereditary;Eye Disorders Congenital;Vision DisordersDrug: QR-421a;Other: Sham-procedureProQR TherapeuticsRecruiting18 YearsN/AAll18Phase 1/Phase 2United States;Belgium;Canada;France
9JPRN-jRCT205118007201/03/20192 April 2019Clinical trial of TK-98 on retinitis pigmentosa: A prospective, randomized, double-blind, placebo-controlled studyClinical trial of TK-98 on retinitis pigmentosa: A prospective, randomized, double-blind, placebo-controlled study - Clinical trial of TK-98 on retinitis pigmentosaretinitis pigmentosa
retinitis pigmentosa;retinitis pigmentosa
Investigational drug (TK-99 or placebo) administration: one packet after every meal (thrice a day);branched-chain amino acidsHanako IkedaRecruiting20 yearsNo maximum age-limitBoth70Phase 2none
10EUCTR2018-002433-38-FR15/02/201930 April 2019Study to evaluate QR-421a in subjects with retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A GeneA First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene - STELLARRetinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene
MedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: QR-421a
Product Code: QR-421a
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Not available
Current Sponsor code: QR-421a
Other descriptive name: QR-421a
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 15-
ProQR TherapeuticsAuthorised Female: yes
Male: yes
18Phase 1;Phase 2United States;France;Canada;Belgium
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2013-005393-22-NL04/01/201928 February 2019A study in subjects with rare inherited eye conditions caused by gene mutations to see if treatment with QLT091001 is safe and works to improve subjects' vision.A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or lecithin:retinol acyltransferase (LRAT) genes
MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 19.0 Level: PT Classification code 10070667 Term: Leber's congenital amaurosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: QLT091001
Product Code: QLT091001
Pharmaceutical Form: Oral solution
INN or Proposed INN: Zuretinol Acetate
Other descriptive name: QLT091001
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
QLT Inc.Not Available Female: yes
Male: yes
48Phase 3France;United States;Canada;Brazil;Denmark;Germany;Netherlands;United Kingdom;Switzerland
12NCT03772938December 13, 201818 December 2018Stem Cells Therapy in Degenerative Diseases of the RetinaStem Cells Therapy in Degenerative Diseases of the RetinaRetinal Degeneration;Retinitis Pigmentosa;Age Related Macular Degeneration;Stargardt Disease 1Biological: Stem/progenitor cells transplantationPomeranian Medical University SzczecinRecruiting18 Years65 YearsAll30Phase 1Poland
13NCT03078309September 201820 August 2018The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa PatientsA Controlled Study of the Effect of Cannabis on Visual Functions in Healthy Subjects and in Retinitis Pigmentosa PatientsRetinitis Pigmentosa;Retinal Degeneration;CannabisDrug: cannabisHadassah Medical OrganizationHebrew University of JerusalemRecruiting18 Years70 YearsAll50Early Phase 1Israel
14NCT03374657August 22, 20187 October 2019A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaAn Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) GeneRetinitis PigmentosaBiological: CPK850Novartis PharmaceuticalsRecruiting18 Years70 YearsAll21Phase 1/Phase 2Sweden
15NCT03566147August 1, 201820 August 2018Treatment of RP and LCA by Primary RPE TransplantationTreatment of Retinitis Pigmentosa and Leber Congenital Amaurosis by Primary Retinal Pigment Epithelial Cells TransplantationLeber Congenital Amaurosis, Retinitis PigmentosaBiological: Human primary Retinal Pigment Epithelial (HuRPE) cellsEyecure Therapeutics Inc.Beijing Tongren HospitalRecruiting18 Years70 YearsAll30Early Phase 1China
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT03316560April 16, 20183 June 2019Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsAn Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR MutationsX-Linked Retinitis PigmentosaBiological: rAAV2tYF-GRK1-RPGRApplied Genetic Technologies CorpRecruiting6 YearsN/AMale30Phase 1/Phase 2United States
17NCT03328130November 6, 201722 July 2019Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B GeneSafety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß ExpressionRetinitis PigmentosaBiological: AAV2/5-hPDE6BHorama S.A.Recruiting18 YearsN/AAll15Phase 1/Phase 2France
18EUCTR2016-001429-16-FR28/07/201716 October 2017Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression.Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression.Retinitis Pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11]Product Code: HORA-PDE6B (AAV2/5.hPDE6B)
Pharmaceutical Form: Solution for injection
HORAMA SAAuthorisedFemale: yes
Male: yes
Phase 1;Phase 2France
19EUCTR2016-003967-21-GB09/06/201711 December 2017Gene Therapy Trial for People with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X.An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy of adults and children with X-linked Retinitis Pigmentosa owing to defects in Retinitis Pigmentosa GTPase Regulator (RPGR) - Gene Therapy Trial for People with Retinitis Pigmentosa: RPGRX-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
MedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: AAV2/5-hRKp.RPGR
Pharmaceutical Form: Solution for injection
INN or Proposed INN: AAV2/5-hRKp.RPGR
Current Sponsor code: AAV2/5-hRKp.RPGR
Concentration unit: billion organisms/ml billion organisms/millilitre
Concentration type: up to
Concentration number: 1000-
MeiraGTx UK II LimitedAuthorisedFemale: no
Male: yes
36Phase 1;Phase 2United Kingdom;United States
20NCT03116113March 16, 20172 September 2019A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis PigmentosaA Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaBiological: AAV8-RPGRNightstaRx LtdRecruiting10 YearsN/AMale63Phase 2/Phase 3United States;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03073733March 1, 201718 March 2019Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis PigmentosaA Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)Retinitis PigmentosaBiological: human retinal progenitor cells;Other: Mock injectionjCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)Not recruiting18 YearsN/AAll84Phase 2United States
22NCT03063021February 15, 201725 March 2019The FIGHT-RP1 StudyA Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)Retinitis PigmentosaDrug: N-Acetyl Cysteine (NAC)Johns Hopkins UniversityNot recruiting18 YearsN/AAll30Phase 1United States
23EUCTR2016-003852-60-GB09/01/20177 January 2019A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa using AAV8A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) - XIRIUS StudyX-Linked retinitis pigmentosa (XLRP)
MedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: AAV8-RPGR
Product Code: AAV8-RPGR
Pharmaceutical Form: Suspension for injection
NightstaRx LimitedAuthorisedFemale: no
Male: yes
63Phase 1;Phase 2;Phase 3United States;United Kingdom
24EUCTR2013-005393-22-DK03/11/201612 December 2016A study in subjects with rare inherited eye conditions caused by gene mutations to see if treatment with QLT091001 is safe and works to improve subjects' vision.A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or lecithin:retinol acyltransferase (LRAT) genes
MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 19.0 Level: PT Classification code 10070667 Term: Leber's congenital amaurosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: QLT091001
Product Code: QLT091001
Pharmaceutical Form: Oral solution
INN or Proposed INN: Zuretinol Acetate
Other descriptive name: QLT091001
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
QLT Inc.AuthorisedFemale: yes
Male: yes
48Phase 3France;United States;Canada;Brazil;Denmark;Netherlands;Germany;United Kingdom;Switzerland
25EUCTR2016-002523-28-GB16/09/20166 February 2017A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa.A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa - Iluvien for IRDRetinitis Pigmetosa.
MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Trade Name: Iluvien
Product Name: Iluvien
Product Code: n/a
Pharmaceutical Form: Implant
INN or Proposed INN: Fluocinolone Acetonide
CAS Number: 67-73-2
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.19-
Moorfields Eye HospitalAuthorisedFemale: yes
Male: yes
Phase 2United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26JPRN-UMIN0000226862016/07/0122 July 2019The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis PigmentosaThe Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa - The Clinical Efficacy in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosaretinitis pigmentosa1% dorzolamide eye drop three times daily in each eye
0.1% betamethasone sodium phosphate eye drop three times daily in each eye
oral 250mg acetazolamide two tablets daily
40mg triamcinolone acetonide into the sub-Tenon capsule
Kyushu University HospitalNot Recruiting20years-oldNot applicableMale and Female40Not applicableJapan
27NCT02837640June 20168 August 2016Studying a Potential Protective Effect of L-Dopa on Retinitis PigmentosaThe Effect of L-Dopa on the Progression of Retinitis PigmentosaRetinitis PigmentosaDrug: levodopa-carbidopaBeirut Eye Specialist HospitalRecruiting10 Years65 YearsBoth50Phase 2Lebanon
28EUCTR2015-003723-65-GB12/01/201628 February 2019Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eyeAflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOURRetinitis Pigmentosa associated Cystoid Macular Oedema
MedDRA version: 18.1 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Eylea
Product Name: Eylea
Product Code: n/a
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Aflibercept
CAS Number: 862111-32-8
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 40-
Moorfields Eye HospitalNot Recruiting Female: yes
Male: yes
30Phase 2United Kingdom
29NCT02556736December 14, 20152 September 2019RST-001 Phase I/II Trial for Advanced Retinitis PigmentosaPhase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)Advanced Retinitis PigmentosaDrug: RST-001AllerganRecruiting18 YearsN/AAll21Phase 1/Phase 2United States
30NCT02464436December 20154 March 2019Safety and Tolerability of hRPC in Retinitis PigmentosaFirst-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)Retinitis PigmentosaDrug: hRPCReNeuron LimitedRecruiting18 YearsN/AAll21Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT02320812June 201518 March 2019Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis PigmentosaA Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)Retinitis Pigmentosa (RP)Biological: human retinal progenitor cellsjCyte, IncCalifornia Institute for Regenerative Medicine (CIRM)Not recruiting18 YearsN/AAll28Phase 1/Phase 2United States
32NCT02465749May 201529 June 2015Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis PigmentosaClinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis PigmentosaRetinitis PigmentosaDrug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tidSun Yat-sen UniversityZhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd.Not recruiting18 Years60 YearsBoth404Phase 0China
33NCT02609165May 201516 December 2017Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaNerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II TrialRetinitis Pigmentosa;Cystoid Macular EdemaDrug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye dropsOspedale San RaffaeleDompé Farmaceutici S.p.ANot recruiting18 YearsN/AAll45Phase 2Italy
34NCT02338973January 14, 201526 August 2019Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)Inherited Ophthalmic Diseases;Inherited Retinal DegenerationDrug: Interferon gamma-1bNational Eye Institute (NEI)Not recruiting12 YearsN/AAll4Phase 1/Phase 2United States
35NCT02804360January 201527 June 2016Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective StudyDexamethasone in Retinitis Pigmentosa Cystoid Macular EdemaRetinitis Pigmentosa;Cystoid Macular EdemaDevice: dexamethasone injectionRafic Hariri University HospitalRecruiting16 Years90 YearsBoth50Phase 2
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT02244996November 201416 December 2017Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium BarbarumCone Rescue in Retinitis Pigmentosa by the Treatment of Lycium BarbarumRetinitis PigmentosaDietary Supplement: Lycium Barbarum;Dietary Supplement: PlaceboThe Hong Kong Polytechnic UniversityThe University of Hong KongRecruiting18 Years70 YearsAll60Phase 2Hong Kong
37NCT02280135November 201416 December 2017Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis PigmentosaPhase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis PigmentosaRetinitis PigmentosaBiological: Intravitreal injection of Autologous bone marrow Stem Cell;Other: Subconjunctival injection of salineRed de Terapia CelularSpanish National Health System;Hospital Universitario Virgen de la Arrixaca;Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia;Public Health Service, Murcia;Instituto Murciano de Investigación Biosanitaria Virgen de la ArrixacaNot recruiting18 Years70 YearsAll8Phase 1Spain
38EUCTR2014-000385-22-IT07/10/201423 March 2015Nerve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa.Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial. - NEMORetinitis pigmentosa with cystoid macular edema
MedDRA version: 17.0 Level: LLT Classification code 10054467 Term: Macular edema System Organ Class: 100000004853
MedDRA version: 17.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Product Name: recombinant human Nerve Growth Factor (rhNGF)
Pharmaceutical Form: Eye drops, solution
INN or Proposed INN: not yet assigned
Other descriptive name: RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF)
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 0.18-
Pharmaceutical form of the placebo: Eye drops, solution
Route of administration of the placebo: Ocular use
Ospedale San Raffaele di MilanoAuthorisedFemale: yes
Male: yes
Phase 2Italy
39NCT01914913September 201419 February 2015Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis PigmentosaAn Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical TrialRetinitis PigmentosaBiological: BMMNCsChaitanya Hospital, PuneRecruiting18 Years65 YearsBoth15Phase 1/Phase 2India
40NCT02140164May 201416 December 2017Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis PigmentosaPilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis PigmentosaRetinitis PigmentosaDrug: MinocyclineNational Eye Institute (NEI)The EMMES CorporationNot recruiting12 YearsN/AAll7Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT02709876April 201418 June 2018Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis PigmentosaRetinitis PigmentosaBiological: Stem Cell TransplantationStem Cells ArabiaNot recruiting18 Years55 YearsAll50Phase 1/Phase 2Jordan
42NCT02110225January 201420 August 2018A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP.Retinitis PigmentosaDrug: rhNGF 60 µg/ml eye drops solution;Drug: rhNGF 180 µg/ml eye drops solution;Drug: PlaceboDompé Farmaceutici S.p.ANot recruiting18 YearsN/AAll50Phase 1/Phase 2Italy
43NCT01786395March 20138 February 2016Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaPhase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration PeriodRetinitis PigmentosaDrug: UF-021;Drug: PlaceboR-Tech Ueno, Ltd.Not recruiting20 Years70 YearsBoth202Phase 3Japan
44EUCTR2012-002436-82-ES13/12/20127 January 2013Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis PigmentosaMelatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis PigmentosaTo evaluate the sleep quality in patients with Retinitis Pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11]Trade Name: CIRCADIN 2 mg comprimidos de liberación prolongada
Product Name: Circadin 2 mg
Pharmaceutical Form: Prolonged-release tablet
INN or Proposed INN: Not answered
CAS Number: 73-31-4
Current Sponsor code: Not answered
Other descriptive name: MELATONIN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Prolonged-release capsule
Route of administration of the placebo: Oral use
Isabel Pinilla LozanoAuthorisedFemale: yes
Male: yes
Spain
45NCT01680510September 20124 March 2019The Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella BardawilThe Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis PigmentosaRetinitis PigmentosaDietary Supplement: Alga Dunaliella Bardawil;Other: Placebo (starch)Sheba Medical CenterRecruiting18 YearsN/AAll100Phase 2/Phase 3Israel
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT01736059July 20121 April 2019Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for RetinopathyA Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From RetinopathyNon-exudative Age-related Macular Degeneration;Diabetic Retinopathy;Retina Vein Occlusion;Retinitis Pigmentosa;Hereditary Macular DegenerationDrug: CD34+ bone marrow stem cells intravitrealUniversity of California, DavisRecruiting18 Years100 YearsAll15Phase 1United States
47NCT01543906February 201219 February 2015Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)Retinitis Pigmentosa (RP)Drug: QLT091001QLT Inc.Not recruiting18 Years70 YearsBoth5Phase 1Canada;Ireland
48NCT01521793January 201219 February 2015Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01)LCA (Leber Congenital Amaurosis);RP (Retinitis Pigmentosa)Drug: QLT091001QLT Inc.Not recruiting5 Years65 YearsBoth27Phase 1United States;Canada;Germany;Netherlands;United Kingdom
49NCT01530659January 201210 December 2018Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaPhotoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and DensityRetinitis Pigmentosa;Usher Syndrome Type 2;Usher Syndrome Type 3Drug: NT-501;Procedure: ShamNeurotech PharmaceuticalsUniversity of California, San Francisco;FDA Office of Orphan Products DevelopmentNot recruiting18 Years55 YearsAll30Phase 2United States
50NCT01560715June 201116 December 2017Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaPhase 2 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaRetinitis PigmentosaBiological: intravitreal injection of autologous bone marrow stem cellsUniversity of Sao PauloNot recruiting18 Years75 YearsAll50Phase 2Brazil
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT01399515March 201125 April 2016Efficacy and Safety of Oral Valproic Acid for Retinitis PigmentosaRetinitis Pigmentosa;Retinal Diseases;Eye Diseases;Eye Disease, Hereditary;Retinal DegenerationDrug: Valproic AcidSeoul National University HospitalNot recruiting18 YearsN/ABoth200Phase 2Korea, Republic of
52JPRN-JMA-IIA0005324/12/20102 April 2019Clinical Trial of Therapeutic Effect of Valproic Acid in Retinitis PigmentosaClinical Trial of Therapeutic Effect of Valproic Acid in Retinitis PigmentosaRetinitis PigmentosaIntervention type:DRUG. Intervention1:Sodium valproate, Dose form:TABLET, Route of administration:ORAL.Yasuhiko HiramiMasayo Takahashi, Yasuo KurimotoNot Recruiting>=20 YEARSNo LimitBOTH30NOT APPLICABLEJapan
53NCT01233609November 201016 December 2017Trial of Oral Valproic Acid for Retinitis PigmentosaA Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis PigmentosaRetinitis PigmentosaDrug: Valproic Acid;Drug: PlaceboFoundation Fighting Blindness Clinical Research InstituteUnited States Department of DefenseNot recruiting18 YearsN/AAll90Phase 2United States
54JPRN-UMIN0000058522010/06/012 April 2019The Clinical Efficacy of a Topical Dorzolamide in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosaretinitis pigmentosa1% dorzolamide three times daily in each eye during the follow-up periodKyushu university hospitalNot Recruiting20years-oldNot applicableMale and Female20Not applicableJapan
55EUCTR2010-019079-32-PT19/05/201016 February 2015A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemA Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery SystemPatients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration).Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9715X
Pharmaceutical Form: Implant
INN or Proposed INN: Brimonidine Tartrate
CAS Number: 70359-46-5
Current Sponsor code: AGN 190342-LF
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Implant
Route of administration of the placebo: Intravitreal use
Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9742X
Pharmaceutical Form: Implant
INN or Proposed INN: Brimonidine Tartrate
CAS Number: 70359-46-5
Current Sponsor code: AGN 190342-LF
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 200-
Pharmaceutical form of the placebo: Implant
Route of administration of the placebo: Intravitreal use
Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System
Product Code: 9741X
Pharmaceutical Form: Implant
INN or Proposed INN: Brimonidine Tartrate
CAS Number: 70359-46-5
Current Sponsor code: AGN 190342-LF
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 400-
Pharmaceutical form of the placebo: Implant
Route of administration of the placebo: Intravitreal use
Allergan LimitedNot RecruitingFemale: yes
Male: yes
290Portugal;Czech Republic;Germany;Italy;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT01014052November 200919 February 2015Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) MutationsPhase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)LCA (Leber Congenital Amaurosis);RP (Retinitis Pigmentosa)Drug: QLT091001QLT Inc.Not recruiting5 Years65 YearsBoth32Phase 1United States;Canada;Germany;Netherlands;United Kingdom
57EUCTR2008-004561-26-IT01/06/200919 March 2012Inner Retinal Dysfunction of the Cone System in Inherited Photoreceptor Degenerations: A Study of Disease Sequence and Assessment of Novel Therapeutic Strategies. - NDInner Retinal Dysfunction of the Cone System in Inherited Photoreceptor Degenerations: A Study of Disease Sequence and Assessment of Novel Therapeutic Strategies. - NDretinitis pigmentosa
MedDRA version: 9.1 Level: LLT Classification code 10038914 Term: Retinitis pigmentosa
MedDRA version: 9.1 Level: PT Classification code 10038914 Term: Retinitis pigmentosa
Product Name: Nerve Growt Factor - 2.5S
Pharmaceutical Form: Eye drops, solution
CAS Number: 93928-24-6
Current Sponsor code: N 6009
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Eye drops, solution
Route of administration of the placebo: Ocular use
Pharmaceutical Form: Eye drops, solution
INN or Proposed INN: COQUN
Concentration unit: % percent
Concentration type: equal
Concentration number: .1-
Pharmaceutical form of the placebo: Eye drops, solution
Route of administration of the placebo: Ocular use
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLIAuthorisedFemale: yes
Male: yes
Italy
58NCT01068561May 200919 February 2015Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaPhase 1 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaRetinitis PigmentosaBiological: intravitreal injection of autologous bone marrow stem cellsUniversity of Sao PauloNot recruiting18 YearsN/ABoth5Phase 1Brazil
59JPRN-UMIN0000068202009/02/012 April 2019Neuroprotective efficacy of topical unoprostone isopropyl or nipradilol in patients with retinitis pigmentosaretinitis pigmentosa0.12% topical unoprostone isopropyl twice daily
0.25% topical nipradilol twice daily
Kyushu university hospitalNot RecruitingNot applicableNot applicableMale and Female50Not selectedJapan
60NCT01773278December 200814 October 2019Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)Smith-Lemli-Opitz Syndrome;Cone-Rod Dystrophy;Hearing LossDrug: Antioxidants;Drug: CholesterolUniversity of Colorado, DenverRecruitingN/A65 YearsAll100Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61JPRN-JapicCTI-09074801/10/200823 April 2019Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosaPhase II Study of 0.15% UF-021 in patients with retinitis pigmentosaretinitis pigmentosaIntervention name : UF-021 (isopropyl unoprostone)
Dosage And administration of the intervention : Eye drop
R-Tech Ueno, Ltd2065BOTH105Phase 2
62NCT01256697August 200819 February 2015The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis PigmentosaThe Effect of Oral Administration of 9-cis Rich Powder of the Alga DunaliellaRetinitis PigmentosaDietary Supplement: Alga Dunaliella Bardawil;Dietary Supplement: Alga Dunaliella Bardawill;Other: Sugar pillSheba Medical CenterNot recruiting18 YearsN/AFemale34N/AIsrael
63NCT00661479July 200819 October 2017An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis PigmentosaRetinitis PigmentosaDrug: 400 µg Brimonidine Tartrate Implant;Drug: 200 µg Brimonidine Tartrate Implant;Drug: 100 µg Brimonidine Tartrate Implant;Other: Sham (no implant)AllerganNot recruiting18 YearsN/AAll21Phase 1/Phase 2United States;France;Germany;Portugal
64NCT00458575April 200719 February 2015A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis PigmentosaA Phase I Open Label Non-comparative Study Evaluating the Safety of a Single, Unilateral, Subretinal Administration of CNTO 2476 in Advanced Retinitis PigmentosaRetinitis PigmentosaDrug: CNTO 2476Centocor, Inc.Not recruiting18 YearsN/ABoth7Phase 1United States
65NCT00433277February 200719 February 2015Autoimmunity in Retinitis PigmentosaRetinitis PigmentosaDrug: twice-daily dosage with 0.5% cyclosporine-A eyedropsSemmelweis UniversityNot recruitingN/AN/ABothN/AHungary
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT00447980January 200728 November 2016A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaA Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary OutcomeRetinitis PigmentosaDrug: NT-501Neurotech PharmaceuticalsNot recruiting18 Years64 YearsBoth68Phase 2United States
67NCT00447993January 200728 November 2016A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaA Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary OutcomeRetinitis PigmentosaDrug: NT-501Neurotech PharmaceuticalsNot recruiting18 Years68 YearsBoth65Phase 2United States
68NCT00100230September 200419 October 2017DHA and X-Linked Retinitis PigmentosaInvestigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis PigmentosaRetinitis Pigmentosa;X-linked Genetic DiseasesDrug: docosahexaenoic acid OR corn/soy oil placeboRetina Foundation of the SouthwestFoundation Fighting Blindness;DSM Nutritional Products, Inc.Not recruiting7 Years32 YearsMale78Phase 2United States
69NCT00461435January 200419 February 2015Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis PigmentosaSlowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis PigmentosaRetinitis PigmentosaProcedure: hyperbaric oxygen therapyAzienda Policlinico Umberto INot recruiting20 Years70 YearsBothN/AItaly
70NCT00065455July 17, 200316 December 2017Investigating the Effect of Vitamin A Supplementation on Retinitis PigmentosaPilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis PigmentosaRetinitis PigmentosaDrug: Vitamin ANational Eye Institute (NEI)Not recruiting18 YearsN/AAll11Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT00346333July 200319 October 2017Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin ARandomized Clinical Trial for Retinitis PigmentosaRetinitis PigmentosaDrug: Lutein;Dietary Supplement: Cornstarch controlNational Eye Institute (NEI)Not recruiting18 Years60 YearsAll240Phase 3United States
72NCT00063765June 200319 February 2015Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the EyeA Phase I Study of NT-501-10 and NT-501-6A.02, Implants of Encapsulated Human NTC-210 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Patients With Retinitis PigmentosaRetinitis PigmentosaDrug: Ciliary Neurotrophic Factor Implant NT-501National Eye Institute (NEI)Not recruitingN/AN/ABoth10Phase 1United States
73JPRN-UMIN0000078952001/07/012 April 2019Effects of nilvadipine on the progression of visual field defects in patients with retinitis pigmentosaretinitis pigmentosaTreated group: oral administration of nilvadipine 4mg per day

Control group: herenien, tocoferol or no medication as patients' requests
Department of Ophthalmology, Hirosaki University Graduate School of MedicineNot Recruiting20years-old80years-oldMale and Female40Phase 2Japan
74NCT00029289April 200119 February 2015Effects of Lutein in Retinitis PigmentosaEffects of Lutein in Retinitis PigmentosaRetinitis PigmentosaDrug: Lutein (10 or 30 mg/day) capsulesNational Center for Complementary and Integrative Health (NCCIH)Not recruitingPhase 1/Phase 2United States
75NCT00000116May 199619 February 2015Randomized Trial for Retinitis PigmentosaRandomized Trial for Retinitis PigmentosaRetinitis PigmentosaDrug: Vitamin A;Drug: Nutritional SupplementNational Eye Institute (NEI)Not recruiting18 Years56 YearsBothPhase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT00004827March 19967 April 2015Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis PigmentosaRetinitis PigmentosaDrug: docosahexaenoic acidRetina Foundation of the SouthwestNot recruitingN/AN/AMale46N/A
77NCT00000114May 198419 February 2015Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis PigmentosaRetinitis PigmentosaDrug: Vitamin E;Drug: Vitamin ANational Eye Institute (NEI)Not recruiting18 Years49 YearsBothPhase 3
78JPRN-JapicCTI-1320792 April 2019Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration PeriodPhase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration PeriodRetinitis PigmentosaIntervention name : UF-021(isopropyl unoprostone)
Dosage And administration of the intervention : Eye drop
Control intervention name : null
R-Tech Ueno, Ltd2070BOTHPhase 3

先頭へ